COMP <GO>
ANGO vs RCEL // EV/EBITDA & P/E VALUATION
AngioDynamics Inc. (NASDAQ) VS. Avita Medical Inc. (NASDAQ) • 15-METRIC TALLY: ANGO 6
— RCEL 3
■ METRIC PARITY
LAST: $12.35 (+1.81%) • MKT CAP: $519.4M
valuation
—
LAST: $16.71 (+1.27%) • MKT CAP: $516.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANGO VS. RCEL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANGO | RCEL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 82.10% | -27.50 | RCEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.40% | -35.00% | +11.60 | ANGO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.10% | -6.23% | +6.33 | ANGO | /fcf-yield <GO> |
| Operating Margin | -12.50% | -59.40% | +46.90 | ANGO | /operating-margins <GO> |
| Net Profit Margin | -11.50% | -60.00% | +48.50 | ANGO | /net-margins <GO> |
| Revenue Growth (YoY) | 9.50% | 11.50% | -2.00 | RCEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.12 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | ANGO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.4 | 66.2 | -26.74 | RCEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $519.4M | $516.8M | $2.6M | ANGO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANGO REV | RCEL REV | ANGO GROSS % | RCEL GROSS % | ANGO FCF | RCEL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $320.2M | $71.6M | 54.6% | 82.1% | $508.0K | -$32.2M |
| FY 2024 | $292.5M | $64.3M | 53.9% | 85.8% | -$14.6M | -$58.1M |
| FY 2023 | $303.9M | $50.1M | — | — | -$28.2M | -$38.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANGO // BETA —
RCEL // BETA —